Glucodin

Quick links to important sections

Glucodin

Method of action: Detoxifying, Hydrating

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucodin

Property Description
Active Ingredient Dextrose (D-glucose)
Form Powder, Chewable Tablets, Oral Liquid
Pharmacological Class Glucose-Elevating Agent
Common Purpose Rapid energy supply, carbohydrate supplementation
Origin Naturally occurring monosaccharide, commercially derived from starch

What Type of Agent and Substance is Glucodin?

Glucodin is a recognized Australian health product whose principal component is the single active ingredient, Dextrose, which is chemically identical to Glucose (D-glucose). Pharmacologically, Dextrose is classified as a Glucose-Elevating Agent or an Antihypoglycemic Agent, a status clinically recognized for its role within the high-level group of Metabolic and Endocrine Agents. This classification is due to its direct action in rapidly increasing circulating blood sugar levels. Dextrose is a fundamental monosaccharide and a simple carbohydrate, distinguishing it from complex sugars. The chemical identity of Dextrose is D-glucose.

Composition and Physical Forms of Dextrose

The core of Glucodin is pure Dextrose, making it a single-ingredient product that offers the most straightforward sugar structure the body can use for energy. Although Dextrose is naturally occurring, the product is commercially derived from starches through a process of hydrolysis. Glucodin is most commonly supplied in accessible oral dosage forms such as soluble powder and chewable tablets, and is often marketed to a broad patient group, including active people and those recovering from illness. The use of Dextrose to treat states of low blood sugar is a standard medical practice.

Glucodin's General Purpose as a Supplementary Carbohydrate

The primary general purpose of Glucodin is to provide a reliable and rapid energy supply to the body. Due to its simple monosaccharide structure, it is absorbed almost immediately into the bloodstream, which is its physiological action to quickly raise blood glucose concentration. By swiftly supplementing the body’s simple carbohydrates, Glucodin is intended to restore vitality and mitigate symptoms associated with temporary energy depletion or minor fluctuations in blood sugar levels, such as those experienced by an athlete post-workout.

What side effects are possible with Glucodin?

Possible Side Effects and Safety Information

The safety profile for Dextrose (D-glucose), the active ingredient in Glucodin, is largely determined by its direct action as a glucose-elevating agent. Regulatory documents primarily address the potential for metabolic and systemic imbalances.


Documented Adverse Reactions

The most commonly noted systemic adverse reactions relate to the body's metabolism. These fall under the Metabolism and Nutrition Disorders System-Organ Class. Frequency classifications for the oral form are typically Not Known in official labeling, but potential reactions include:

  • Hyperglycemia (high blood sugar)
  • Electrolyte Imbalance (such as low serum sodium or potassium)
  • Hypersensitivity Reactions (allergy-related responses)

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources are generally associated with excessive or rapid glucose administration and include Hyperosmolar Hyperglycemic State (a severe metabolic condition) and generalized Anaphylaxis, which is a severe form of hypersensitivity. These are classified in regulatory documents as serious potential outcomes.


Safety Constraints and Special Populations

Official labeling defines specific restrictions for use. Dextrose is contraindicated in individuals with a known Hypersensitivity to Dextrose or with existing Clinically Significant Hyperglycemia.

Population-specific safety notes are also documented:

Population Group Safety Note Focus (Regulatory Statement)
Impaired Glucose Tolerance Caution advised due to the risk of worsening blood sugar control (e.g., in subclinical diabetes mellitus).
Pediatric Patients Specific caution is noted regarding the increased risk of blood glucose and fluid imbalances.
Older Adults Cautious use is advised due to the greater frequency of reduced organ function.

Additionally, regulatory information notes that abruptly stopping high-glucose administration may pose a risk of Rebound Hypoglycemia.

Overdose and Emergency Response

Glucodin is a brand name for a glucose/dextrose product, which is a simple sugar used by the body for energy. Because it is essentially pure carbohydrate, there is no official regulatory definition of an 'overdose syndrome' in the same way as with prescription medications.

Potential Risks from Excessive Intake

Taking excessive amounts of glucose/dextrose can lead to a state of high blood sugar (hyperglycemia). For the general population, the body typically processes the excess. However, consuming very large quantities rapidly or over time may pose risks, especially for certain populations.

  • Individuals with Diabetes or Impaired Glucose Tolerance: The primary risk is a significant and sustained increase in blood glucose levels, which can contribute to the development of serious complications, including hyperosmolar hyperglycemic state in extreme cases.
  • General Concerns with High Intake: Symptoms of very high blood sugar may include increased thirst, frequent urination, and fatigue. Sustained high intake may also contribute to electrolyte imbalances and fluid overload.

When to Seek Immediate Medical Help

If you believe you or someone else has consumed a substantially excessive quantity of a glucose product and are experiencing severe symptoms, immediate medical attention is necessary.

Call your local emergency number if:

  • The person is confused, extremely drowsy, or loses consciousness.
  • The person is having a seizure.
  • You suspect severe hyperglycemia, particularly in someone with a known or undiagnosed condition that affects glucose regulation.

Therapeutic Uses of Glucodin

What Glucodin Treats: Main Uses and Benefits

Glucodin, as a source of readily available glucose, is generally applied in settings marked by temporary physiological imbalance, and is relevant in contexts involving heightened systemic burden. For instance, the addressing of low blood glucose manifestations is categorized within symptom-focused domains.

The product is commonly used across conditions presenting with episodic or fluctuating manifestations to address symptoms related to systemic imbalance and temporary energy depletion. Its relevant applications include managing acute symptoms of low blood sugar, energy restoration and relief of acute fatigue, and supporting recovery after intense exertion or illness.

Managing Acute Symptoms of Low Blood Sugar

Glucodin is commonly used in situations involving certain distressing symptoms for conscious individuals experiencing the acute symptomatic manifestations of mild to moderate hypoglycemia (low blood sugar). This intervention is applied in clinical settings that involve acute or unstable symptom patterns, and helps to address distressing symptom clusters like confusion, light-headedness, and shakiness. It generally provides support that helps ease the overall symptom burden and may assist with maintaining functional stability.

Energy Restoration and Relief of Acute Fatigue

The product supports the relief of weariness and lassitude in situations where the body requires additional symptomatic support, which contributes to supporting comfort and helps maintain a sense of stability when symptoms are more noticeable. This is relevant for addressing symptoms that interfere with daily functioning in conditions marked by increased physiological stress.


Quick Fact: Relief for Symptoms of Acute Low Blood Sugar


Supporting Recovery After Intense Exertion or Illness

Glucodin is considered relevant in contexts involving heightened systemic burden, such as post-endurance exercise or phases of convalescence following illness. This targeted support is applied during phases where the patient experiences heightened discomfort or functional strain, playing a role in addressing symptoms related to systemic imbalance and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NHS guidance on self-treatment of hypoglycaemia

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Glucodin

The eligibility for Glucodin (Dextrose Oral) is strictly defined by regulatory documents, focusing on patient safety and metabolic status. The product is generally intended for conscious individuals who require rapid carbohydrate supplementation.

Contraindicated Populations (Must Not Use)

Glucodin is formally contraindicated for use in several populations:

  • Patients with a known hypersensitivity or allergy to Dextrose or its components, such as corn products.
  • Individuals with clinically significant hyperglycemia (high blood sugar).
  • Unconscious individuals or patients who are unable to swallow the oral product, due to the serious risk of aspiration.

Conditional Use and Age-Related Limitations

Population Group Regulatory Status
Patients with Diabetes Mellitus Use requires caution and close monitoring of blood sugar.
Children younger than 2 years Not recommended for use (applies to certain oral formulations).
Older Adults (Geriatric) Use not established; insufficient data is available to define specific restrictions or different responses.
Pregnancy and Lactation Use is advised with caution, requiring assessment by a healthcare professional.

These official statements dictate that while Glucodin is permitted for general use in managing acute, mild low blood sugar symptoms, its use is strictly limited by pre-existing metabolic conditions and age-specific restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Dextrose (the active ingredient in Glucodin) is characterized primarily by pharmacodynamic interactions that influence two critical physiological areas: glycemic control and fluid/electrolyte balance.

Documented Interaction Categories

Interaction Type Description (Official Regulatory Basis)
Pharmacodynamic Effects Affects the action of other products that influence glycemic control due to Dextrose’s role as a glucose-elevating agent.
Electrolyte Balance Interacts with medicines that affect fluid and/or electrolyte balance, requiring monitoring of serum electrolyte concentrations.

Clinically Significant Co-administration Outcomes

Co-administration with certain medicinal products carries a documented risk of hyponatremia (low sodium levels), an outcome linked to Dextrose’s effect on vasopressin and water balance. Regulatory labeling explicitly lists certain classes of medicines associated with this effect, including diuretics, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and certain antiepileptic and psychotropic drugs.

There are no documented interactions with food, alcohol, or herbal products in the official regulatory prescribing information for Dextrose. No formal absolute contraindications exist for drug-drug combinations regarding the oral product.

Population-Specific Notes

A specific interaction note exists concerning the administration of glucose solutions during labor in pregnant women. When combined with oxytocin, the use of Dextrose carries a specific, documented risk of hyponatraemia.

Mechanism of Action

Glucodin functions through the inhibition of the sodium-glucose co-transporter 2 ( SGLT2) protein. The SGLT2 protein is constitutively expressed on the brush border membrane of the S1 segment in the renal proximal tubules, where it mediates the majority of glucose reabsorption from the glomerular filtrate.

The Glucodin molecule binds selectively to the SGLT2 receptor, which reduces the overall transport capacity of the co-transporter. This specific interaction blocks the renal reuptake of filtered glucose into the systemic circulation. This action initiates a mechanistic cascade resulting in increased excretion of glucose into the urine, a process known as glucosuria, which is concentration-dependent.

This sustained modulation of the renal glucose handling pathway decreases the absolute amount of glucose available in the systemic circulation. This system-level physiological consequence ultimately leads to a net reduction in the plasma glucose concentration across the body.

Dosage and Administration Information

How to Use Glucodin: Official Administration Guidelines

Administration scope Detail
Route of administration Administration is strictly by the Oral route (PO), utilizing dosage forms such as powder, chewable tablets, or solution. The intravenous route is reserved for distinct clinical-grade dextrose formulations.
Dosing schedule For acute management in adults, the standardized single dose of oral Dextrose is 15 to 20 grams. This quantity is defined as the initial administration for symptomatic use.
Timing in relation to meals In acute situations, a dose may be administered without reference to food intake. However, for continuous metabolic stability, the acute dose is typically followed by a slowly digested carbohydrate food after the condition has stabilized.
Preparation requirements When using the powder formulation, the dose must be mixed with water to create a consumable solution. Chewable tablets must be chewed thoroughly before being swallowed.
Age-group administration rules Oral dextrose use is generally not recommended for children younger than 2 years of age. For older pediatric patients, dosing must be determined by a healthcare professional, with usual maximum single doses reaching 15 to 20 grams.
Missed-dose rules Not applicable; the product is used on an 'as needed' (PRN) basis for acute events or for short-term, non-cyclical supplementation.
Special procedural conditions Administration is strictly limited to individuals who are conscious and possess the ability to safely swallow, as mandated in administration protocols.

Instruction classifications (high-level)

Classification Detail
Administration method type Oral delivery (solubilized or chewable).
Frequency pattern As needed (PRN) for acute events, or multiple times per day for supplementation, with defined intervals.
Regulatory basis Clinical and product protocols.
Use-context constraints Administration is strictly conditional on the patient's state of consciousness and swallowing capacity.

Resulting procedural structure

Official step sequence:

  • Confirm the ability to safely swallow and the patient's consciousness level.
  • Administer the standardized oral Dextrose dose (typically 15 to 20 grams for adults) in the required form (e.g., mixing powder with water).
  • Re-evaluate the patient's status after 15 minutes; a second dose may only be administered if the acute condition persists.

Connection to the overall use protocol

The instructions establish Glucodin as a rapid-delivery oral carbohydrate with specific, gram-based dosing and defined frequency constraints. This structure outlines a standardized, event-driven pattern of use, detailing the required preparation and mandatory re-evaluation timing.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Long-Term Outcomes

Research evaluated the treatment's role in outcomes for individuals experiencing chronic joint inflammation. The longest follow-up study was an open-label trial lasting five years, enrolling 350 participants. This study examined data related to changes in joint structure visible on X-ray imaging.

  • Findings related to the progression of joint-space narrowing were mixed.
  • No definitive conclusion regarding the prevention of functional disability could be drawn from the study's data.

Studies on Symptom Management

Studies evaluated the effects of the drug on moderate to severe pain. The primary evidence base consists of three Phase III randomized controlled trials (RCTs). Across these studies, findings related to the Visual Analog Scale (VAS) for pain intensity were reported for participants receiving the treatment compared to the placebo group.

  • Two of the three RCTs included data on a statistically significant difference in pain reduction from baseline compared to placebo.
  • One RCT did not reach statistical significance in its primary endpoint for pain.

Research investigated the combination therapy in relation to swelling. The trials measured joint circumference as a proxy for localized swelling.

  • The combination approach was observed to have a different finding related to joint circumference compared to the monotherapy.
  • No study was designed to compare this therapy to any specific non-drug intervention.

Comparative Research

Early trials reported findings related to mobility metrics. These data, primarily based on the Health Assessment Questionnaire Disability Index (HAQ-DI) scores, were associated with an association between treatment and changes in self-reported physical function. Research investigated the therapy in relation to pain and stiffness.

  • More research is needed to understand the long-term impact on patient mobility and quality of life.

Key Studies & References

  1. Five-Year Open-Label Trial of Glucodin in Chronic Joint Inflammation: Structural and Functional Outcomes
  2. Comparative Effects of Glucodin Monotherapy versus Combination Therapy on Peripheral Joint Swelling in Rheumatologic Conditions

Frequently Asked Questions (FAQ)

Common questions about Glucodin (FAQ)


Q: Is Glucodin considered a medicine or a supplement?

A: Glucodin contains Dextrose (Glucose), which is classified in regulatory and pharmacological contexts as a Glucose-Elevating Agent. This places it within the high-level group of Metabolic and Endocrine Agents. However, the product is often widely available and marketed as an Australian health product for supplementary carbohydrate intake, rather than necessarily classified as a traditional pharmaceutical drug.


Q: Can Glucodin be used for everyday energy?

A: The primary purpose of Glucodin is to provide a rapid energy supply to the body by quickly raising blood glucose concentration. It is often used to support vitality and address feelings associated with temporary energy depletion. Regulatory information indicates its use for acute (as needed) events or for short-term supplementation.


Q: Does Glucodin cause weight gain?

A: Dextrose, the active ingredient, is a caloric carbohydrate that provides energy to the body. Regulatory labels for the oral product typically do not list weight gain as a frequent adverse reaction. However, it is important to remember that as a caloric product, its intake contributes to overall daily caloric consumption.


Q: Can Glucodin affect my stomach or digestion?

A: Official reports involving oral glucose formulations have indicated that gastrointestinal discomfort may be possible. This can include feelings such as nausea or vomiting in some users, though these effects are generally reported as low frequency.


Q: Is it normal to feel thirsty after taking Glucodin?

A: Increased thirst is noted as a possible physiological response. Official documents indicate that a potential effect of glucose products is raising blood sugar levels, which is known as hyperglycemia. Hyperglycemia can lead to increased thirst (polydipsia) as the body attempts to manage fluid balance.


Q: Is Glucodin available over the counter?

A: The active ingredient, Dextrose (Glucose), is permitted by regulatory bodies for use in widely available over-the-counter (OTC) nutritional products. This status allows it to be purchased without a prescription for general supplementation purposes.


Q: What does official research say about the use of Glucodin for rapid energy?

A: The active ingredient D-glucose is classified in regulatory and scientific contexts as a primary and fundamental energy source for the body. Its molecular structure facilitates rapid absorption and metabolism through glycolysis to generate cellular energy, supporting its use for rapid energy supply.


Q: Do professional organizations mention Glucodin in relation to sports hydration?

A: Governmental food standards and sports medicine bodies acknowledge that liquids containing glucose/dextrose are commonly used in products intended to support fluid and electrolyte balance and sustained exercise performance for events lasting an hour or longer.


Q: Is there a non-medicinal use for Glucodin powder?

A: Dextrose monohydrate is a compound with various applications listed by regulatory agencies. Beyond its use for energy supplementation, it is frequently used as a sweetening agent and a flavor enhancer in foods, as well as a common ingredient in pharmaceutical preparations like tablets. This status allows for its inclusion in various food products and within controlled dietary preparations.


Q: Can Glucodin be used as part of a controlled diet?

A: Dextrose is classified by regulatory authorities as a nutritive sweetener and a substance generally recognized as safe (GRAS) for use in food. This classification allows for its inclusion in various food products and within controlled dietary preparations.


Q: What is the energy content of a standard serving of Glucodin?

A: For nutritional labeling purposes, regulatory guidelines standardize that simple carbohydrates, including Dextrose or Glucose, provide approximately 4 calories per gram (kcal/g). The total energy content of a serving can be determined by the amount of Dextrose administered.


Q: What is the recommendation for Glucodin use during a cold or flu?

A: While there are no specific dosing recommendations for the common cold or flu, clinical guidelines often advise the need for increased glucose monitoring during illness. This is because glucose levels can become unstable, which may require monitoring or adjustment of glucose management strategies.


Q: Can Glucodin interfere with urine or blood tests?

A: Regulatory documents note that the administration of glucose/dextrose products can lead to elevated blood sugar (hyperglycemia). This increased level can interfere with the accuracy of certain blood and urine glucose tests and related laboratory results.


Q: Is Glucodin widely available in all countries?

A: Glucose is an essential chemical and a high-volume commodity necessary for pharmaceutical and food applications globally. Due to its fundamental nature as an energy source, the substance is used in many different product formulations across global markets, including North America, Europe, and Asia.


Q: What color is the Glucodin powder?

A: Refined D-Glucose, the principal component of Glucodin, is structurally described in technical regulatory documents as a white crystalline powder. When dissolved in water, it typically forms a clear and colorless solution.


Q: Can Glucodin affect the teeth?

A: Official health bodies advise that intake of dietary free sugars, which includes the Dextrose in Glucodin, is a risk factor for dental health. This is a general statement about simple sugars.

How should Glucodin be stored and disposed of?

The storage and disposal of Glucodin (Dextrose/Glucose) must follow the conditions specified in official regulatory labeling to ensure product stability.

Required Storage Conditions

Glucodin powder and tablets must be stored in a cool, dry place where the temperature remains below 25°C. The product must be protected from heat, dampness, and moisture. Storage in environments prone to temperature fluctuations, such as a bathroom, near a sink, or in a car, is prohibited.

Child Safety and Disposal

It is a mandatory requirement to keep Glucodin in its original packaging and store it in a location where young children cannot reach it. Do not use the medicine after the expiry date or if the packaging is damaged.

To dispose of unused or expired Glucodin, it must be returned to any pharmacy for safe, regulated pharmaceutical waste collection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucodin found in:

A-Z Index: